Combination therapy with interferon alfa-2b and hydroxyurea during the accelerated phase of chronic myelogenous leukemia

Απλή σελίδα τεκμηρίου
dc.contributor.authorBourantas, K. L.en
dc.contributor.authorSyrou, M.en
dc.contributor.authorTsiara, S.en
dc.contributor.authorDanella, M.en
dc.contributor.authorKonstantinides, P.en
dc.date.accessioned2015-11-24T19:29:32Z
dc.date.available2015-11-24T19:29:32Z
dc.identifier.issn0001-5792-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22978
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectHydroxyurea/*administration & dosageen
dc.subjectInterferon-alpha/*administration & dosageen
dc.subjectLeukemia, Myeloid, Accelerated Phase/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectRecombinant Proteinsen
dc.titleCombination therapy with interferon alfa-2b and hydroxyurea during the accelerated phase of chronic myelogenous leukemiaen
heal.abstractInferferon alfa-2b (IFN) plays a major role in the current management of previously untreated patients with chronic myelogenous leukemia (CML) as well as patients with CML who have relapsed after bone marrow transplantation. Hydroxyurea (HU) is the best conventional drug for treatment of CML in the chronic phase. Ten patients, six men and four women, 40-70 years of age, were treated during the accelerated phase of CML with a combination of IFN and HU. Patients had received only HU during the chronic phase of the disease. All patients were positive for the Philadelphia chromosome and had an excess number of blasts in peripheral blood smears (more than 10%), as well as increased numbers of basophils and eosinophils but a low leukocyte level of alkaline phosphatase. Eight of them had splenomegaly. Five patients (50%) survived for 1-3 years, achieving complete hematological remission. Three patients had a partial hematological response and died within 1-2 years. Two patients with aggressive disease died within 3 months of the blastic crisis. It appears that combination therapy with IFN and HU might be a useful alternative for patients in the accelerated phase of CML who have failed to respond to HU alone.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8638440-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000203859-
heal.journalNameActa Haematolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1996-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ